TIDMVSN
RNS Number : 9167P
Verseon Corporation
23 November 2016
For immediate release 23 November 2016
Verseon Corporation
("Verseon" or the "Company")
Preclinical research to be presented at ASH Annual Meeting shows
Verseon's new class of anticoagulants prevents thrombosis while
preserving platelet function
Fremont, Calif.-Preclinical research from Verseon, to be
presented at the American Society of Hematology (ASH) Annual
Meeting on December 5(th) , 2016, shows that the Company's new
class of direct thrombin inhibitors (VE-DTIs) are able to preserve
platelet function. These findings provide a rationale why the
VE-DTIs have a significantly reduced bleeding risk when compared to
current novel oral anticoagulants (NOACs) in preclinical
testing.
The key finding of this study is that Verseon's potent, highly
selective direct thrombin inhibitors do not disrupt platelet
function, while they still block fibrinogen cleavage. NOACs are
associated with bleeding risk and are known to strongly inhibit
thrombin-mediated platelet activation, hence affecting platelet
function. Compared to the NOACs, the VE-DTIs inhibit
thrombin-mediated platelet activation from 19- to 900-fold less
strongly.
While the VE-DTIs preserve platelet function, preclinical
studies show that they act as effective anticoagulants, preventing
arterial and venous thromboembolism, as well as thrombin-induced
pulmonary embolism, with efficacy comparable to that of existing
anticoagulants.
"Maintaining platelet function while preventing thrombosis could
be an important approach to reduce bleeding risk. This work may
lead to a new generation of safer blood thinners," said Dr. John
Deanfield, Professor of Cardiology at University College, London,
who chairs Verseon's cardiology advisory board.
Earlier this month at the American Heart Association (AHA)
Scientific Sessions, Verseon presented a poster which demonstrated,
in preclinical testing, that one of their lead drug candidates
shows favorable safety, toxicity, and pharmacokinetics, including
very low renal clearance of less than 10%. Low renal clearance
would be highly desirable for patients with impaired renal
function. Reported renal clearances for current NOACs, apixaban,
rivaroxaban, edoxaban, and dabigatran, range from 27% to 80%. The
poster also featured a single oral dose tolerability study for this
compound, which established a high maximum tolerated dose in vivo.
Moreover, a preclinical seven-day repeat dose-range finding study,
with oral dosing once a day, indicates that the compound is well
tolerated.
Verseon CEO Adityo Prakash, speaking about drug discovery and
development at the Financial Times Global Pharmaceutical and
Biotechnology Conference in London last week, explained that this
new class of anticoagulants has been developed using Verseon's
proprietary, computationally driven drug discovery platform. "We
built our platform to provide better drug candidates through the
generation of genuinely novel chemical matter," said Prakash. "The
results shown at AHA and to be presented at ASH continue to
validate our drug discovery process, which is producing a series of
new drug candidates on an ongoing basis. In addition to our
anticoagulant program, we currently also have programs on diabetic
macular edema and oncology in preclinical testing, all with
multiple novel drug candidates."
Verseon's abstract is available on the conference website and
will be published in Blood on December 1, 2016. Details of the ASH
poster presentation are as follows:
Abstract title: "Novel Class of Direct Thrombin Inhibitors
Prevent Thrombosis by Inhibiting Fibrinogen Cleavage While
Preserving Platelet Function"
Abstract Number: #3834
Session Name: 332. Antithrombotic Therapy: Poster III
Date and Time: December 5, 2016, 6:00-8:00 p.m.
Location: San Diego Convention Center, Hall GH
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that employs its
proprietary, computational drug discovery platform to develop novel
therapeutics that are unlikely to be found using conventional
methods. The Company is applying its platform to a growing drug
pipeline and currently has three active drug programs in the areas
of anticoagulation, diabetic macular edema, and oncology.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Arthur Shmurun / Amy Thai 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Mark Connelly / Steve Cox 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
Mirabaud Securities LLP (Joint
Broker)
+44 (0) 20
Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Sophie +44 (0) 20
Cowles 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions, and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGGGUGUPQUMW
(END) Dow Jones Newswires
November 23, 2016 02:03 ET (07:03 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024